What to Know About Tysabri and PML: What Evidence Can and Cannot Show
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Education to Specific Legal Timelines
If you or a loved one developed progressive multifocal leukoencephalopathy (PML) after taking Tysabri, you likely have questions about how this rare brain infection is linked to the medication. Decades of pharmacovigilance have established that certain immunosuppressive therapies carry a known risk of PML, but the precise chain of causation can be complex. This page reviews what the evidence can and cannot demonstrate regarding Tysabri and PML, helping you understand the medical and legal landscape.
Medical Evidence: Tysabri and PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus, which typically remains dormant in immunocompetent individuals but can reactivate in patients receiving immunosuppressive therapies. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information emphasizes that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and vision changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists frequent reports of fatigue, multiple sclerosis relapse, headache, gait disturbance, balance disorder, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms can overlap with multiple sclerosis itself, PML should be suspected when new or worsening neurological signs appear during treatment. The mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing JC virus reactivation and replication in the brain. This mechanistic pathway is well-established in the medical literature and is reflected in the FDA's boxed warning.
For individuals in Michigan who have been diagnosed with PML after Tysabri treatment, consulting with an attorney experienced in pharmaceutical litigation is advisable. Key legal considerations include: - **Statute of limitations**: In Michigan, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, the date of diagnosis is typically the starting point. However, because PML can develop insidiously, the exact timeline between exposure and documented harm is important. The FDA notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should gather medical records documenting the start of Tysabri therapy, the date of PML diagnosis, and any prior immunosuppressant use. - **Product liability theories**: Claims may be based on failure to warn, design defect, or negligence. The adequacy of the boxed warning and the TOUCH program's implementation may be scrutinized. - **Damages**: PML often results in severe disability or death, leading to significant medical expenses, lost income, and pain and suffering.
Timeline Between Exposure and Documented Harm
The risk of PML increases with cumulative Tysabri exposure. The prescribing information states that "longer treatment duration, especially beyond 2 years" is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur earlier, particularly in patients with anti-JCV antibodies or prior immunosuppressant use. The FDA's boxed warning advises that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For legal purposes, the timeline from first Tysabri infusion to PML diagnosis is critical for establishing causation and meeting the statute of limitations.
Conclusion
Tysabri-associated PML is a severe, often fatal condition with well-defined risk factors. Michigan patients who have developed PML should seek prompt medical and legal evaluation. The statute of limitations in Michigan is generally three years from discovery of the injury, but individual circumstances vary. Consulting with an attorney who understands both the medical complexities of PML and Michigan's legal deadlines is essential.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Michigan?
In Michigan, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, the date of diagnosis is typically the starting point. However, because PML can develop insidiously, the exact timeline between exposure and documented harm is important. Patients should gather medical records documenting the start of Tysabri therapy, the date of PML diagnosis, and any prior immunosuppressant use.
What are the risk factors for developing PML while on Tysabri?
Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.